Literature DB >> 14706249

Development of a perillyl alcohol topical cream formulation.

Abhishek Gupta1, Paul B Myrdal.   

Abstract

Perillyl alcohol (POH) is a relatively non-toxic agent that has been shown to be a promising anticancer monoterpene in preclinical models. Studies have indicated that topical application of POH may prove to be effective as a skin cancer chemoprevention therapy. The main aim of this study was to determine the influence of several factors on the stability of POH in solution and develop a topical formulation of POH. During preformulation, the influence of pH, temperature, ionic strength, and organic solvents, on the stability of POH was evaluated at four different temperatures: 4, 25, 37, and 48 degrees C. POH was found to degrade under acidic conditions with degradation following apparent first-order kinetics. A hydrophilic topical cream formulation of POH was developed and prepared for toxicology and clinical studies. A reverse phase gradient HPLC method was developed to quantitate POH in the complex formulation. Stability studies of the formulation and a placebo were performed and the formulation was found to be physically and chemically stable over a period of 1 year at 4 and 25 degrees C.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14706249     DOI: 10.1016/j.ijpharm.2003.09.026

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  9 in total

Review 1.  Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy.

Authors:  Thomas C Chen; Clovis O Da Fonseca; Axel H Schönthal
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

2.  Cell physiology rather than enzyme kinetics can determine the efficiency of cytochrome P450-catalyzed C-H-oxyfunctionalization.

Authors:  Sjef Cornelissen; Shanshan Liu; Amit Tatyasaheb Deshmukh; Andreas Schmid; Bruno Bühler
Journal:  J Ind Microbiol Biotechnol       Date:  2011-05-11       Impact factor: 3.346

3.  Stability of sulforaphane for topical formulation.

Authors:  Stephen J Franklin; Sally E Dickinson; Kelly L Karlage; G T Bowden; Paul B Myrdal
Journal:  Drug Dev Ind Pharm       Date:  2013-04-23       Impact factor: 3.225

4.  A phase 2a study of topical perillyl alcohol cream for chemoprevention of skin cancer.

Authors:  Steven P Stratton; David S Alberts; Janine G Einspahr; Paul M Sagerman; James A Warneke; Clara Curiel-Lewandrowski; Paul B Myrdal; Kelly L Karlage; Brian J Nickoloff; Chris Brooks; Kathylynn Saboda; Michael L Yozwiak; Mary F Krutzsch; Chengcheng Hu; Maria Lluria-Prevatt; Zigang Dong; G Timothy Bowden; Peter H Bartels
Journal:  Cancer Prev Res (Phila)       Date:  2010-01-26

5.  The epoxidation of limonene over the TS-1 and Ti-SBA-15 catalysts.

Authors:  Agnieszka Wróblewska
Journal:  Molecules       Date:  2014-11-28       Impact factor: 4.411

6.  Acute tea tree oil intoxication in a pet cockatiel (Nymphicus hollandicus): a case report.

Authors:  Alessandro Vetere; Mara Bertocchi; Igor Pelizzone; Emanuele Moggia; Chiara Travaglino; Mariangela Della Grotta; Silvia Casali; Sebastiano Gerosa; Laura Strada; Katia Filia; Jacopo Casalini; Enrico Parmigiani; Francesco Di Ianni
Journal:  BMC Vet Res       Date:  2020-01-31       Impact factor: 2.741

7.  Enrichment, development, and assessment of Indian basil oil based antiseptic cream formulation utilizing hydrophilic-lipophilic balance approach.

Authors:  Narayan Prasad Yadav; Jaya Gopal Meher; Neelam Pandey; Suaib Luqman; Kuldeep Singh Yadav; Debabrata Chanda
Journal:  Biomed Res Int       Date:  2013-07-31       Impact factor: 3.411

Review 8.  Waste Tyres Pyrolysis for Obtaining Limonene.

Authors:  Katarzyna Januszewicz; Paweł Kazimierski; Wojciech Kosakowski; Witold M Lewandowski
Journal:  Materials (Basel)       Date:  2020-03-17       Impact factor: 3.623

Review 9.  The Monoterpenoid Perillyl Alcohol: Anticancer Agent and Medium to Overcome Biological Barriers.

Authors:  Thomas C Chen; Clovis O da Fonseca; Daniel Levin; Axel H Schönthal
Journal:  Pharmaceutics       Date:  2021-12-16       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.